Irbesartan Hct Sandoz (Hydrochlorothiazide, Irbesartan)

Irbesartan/Hydrochlorothiazide is used to manage hypertension, a condition characterized by elevated arterial pressure.

• Essential hypertension: lowers systolic and diastolic blood pressure, helping achieve target levels.
• Hypertension requiring combination therapy: provides additive blood pressure reduction when a single agent is insufficient.

• Irbesartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II‑mediated vasoconstriction and aldosterone secretion. Hydrochlorothiazide acts on the distal convoluted tubule to inhibit Na⁺/Cl⁻ reabsorption, increasing urinary sodium and water excretion, which reduces plasma volume. The combined actions produce synergistic reduction of peripheral resistance and circulating volume, resulting in effective blood pressure control.

The combination may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Dizziness or light‑headedness, especially after the first dose.
• Headache.
• Fatigue or mild weakness.
• Increased urination.
• Electrolyte disturbances such as low potassium.
• Mild gastrointestinal upset (nausea, abdominal discomfort).

Serious or Rare Side Effects

• Severe hypotension or syncope.
• Acute kidney injury or significant rise in serum creatinine.
• Hyperkalemia or severe electrolyte imbalance.
• Allergic reactions including rash, angioedema, or anaphylaxis.
• Liver function abnormalities.

Before prescribing Irbesartan/HCTZ, clinicians should consider several safety considerations.

• Renal function: assess baseline kidney function and monitor creatinine and electrolytes.
• Electrolyte balance: check serum potassium and sodium, especially in patients on other diuretics.
• Volume status: avoid in patients prone to dehydration or excessive fluid loss.
• Concomitant medications: caution with other antihypertensives to prevent additive hypotension.
• Pregnancy: avoid use during pregnancy as it may harm the fetus.
• Store below 25°C: keep in the original packaging, protect from moisture and light.

Irbesartan/HCTZ can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid)

• Dual potassium‑sparing agents (e.g., spironolactone, amiloride): risk of hyperkalemia.
• Lithium: increased lithium levels leading to toxicity.
• ACE inhibitors or other ARBs: additive renal effects and hyperkalemia.

Moderate Interactions (Monitor Closely)

• NSAIDs (e.g., ibuprofen, naproxen): may reduce antihypertensive effect and impair renal function.
• Other diuretics: may exacerbate electrolyte disturbances.
• Antidiabetic drugs (e.g., insulin, sulfonylureas): may require dose adjustment due to altered glucose control.